within Pharmacolibrary.Drugs.ATC.D;

model D11AX11
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 8.333333333333333e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D11AX11</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Hydroquinone is a topical skin-lightening agent used primarily to reduce pigmentary skin disorders such as melasma, chloasma, freckles, and age spots. It works by inhibiting melanin production in the skin. Hydroquinone is available in various concentrations for topical use and is currently approved for over-the-counter and prescription use in some countries, though its use is restricted or banned in others due to safety concerns.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult subjects after topical administration based on available pharmacological data; no primary human pharmacokinetic models have been published.</p><h4>References</h4><ol><li><p>Fitton, A, &amp; Goa, KL (1991). Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. <i>Drugs</i> 41(5) 780–798. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199141050-00007&quot;>10.2165/00003495-199141050-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1712709/&quot;>https://pubmed.ncbi.nlm.nih.gov/1712709</a></p></li><li><p>Taheri, A, &amp; Mohammadi, M (2015). The Use of Cellulose Nanocrystals for Potential Application in Topical Delivery of Hydroquinone. <i>Chemical biology &amp; drug design</i> 86(1) 102–106. DOI:<a href=&quot;https://doi.org/10.1111/cbdd.12466&quot;>10.1111/cbdd.12466</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25352376/&quot;>https://pubmed.ncbi.nlm.nih.gov/25352376</a></p></li><li><p>Levitt, J (2007). The safety of hydroquinone: a dermatologist&#x27;s response to the 2006 Federal Register. <i>Journal of the American Academy of Dermatology</i> 57(5) 854–872. DOI:<a href=&quot;https://doi.org/10.1016/j.jaad.2007.02.020&quot;>10.1016/j.jaad.2007.02.020</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17467115/&quot;>https://pubmed.ncbi.nlm.nih.gov/17467115</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D11AX11;
